Mitch Gold, Alpine Immune Sciences CEO

A check­point 2.0 drug runs in­to trou­ble as Alpine gets hit with the lat­est in a string of clin­i­cal holds

The FDA is once again prov­ing that it’s ready to hit the red light on a tri­al in an in­stant when some­thing bad hap­pens to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.